| First Author | Breslin A | Year | 2007 |
| Journal | Biochem Biophys Res Commun | Volume | 363 |
| Issue | 3 | Pages | 462-5 |
| PubMed ID | 17904521 | Mgi Jnum | J:127334 |
| Mgi Id | MGI:3763583 | Doi | 10.1016/j.bbrc.2007.09.052 |
| Citation | Breslin A, et al. (2007) SSX2IP: an emerging role in cancer. Biochem Biophys Res Commun 363(3):462-5 |
| abstractText | We describe the emerging role of Synovial Sarcoma X breakpoint 2 Interacting Protein (SSX2IP) in cancer and its still largely unknown function in human cells. In rodents, SSX2IP has been shown to play a role in adherens junctions and cell adhesion, while in chickens SSX2IP was identified by virtue of its regulation by the light cycle and circadian rhythms. In humans, SSX2IP was identified through its interaction with the cancer-testis gene SSX2. However SSX2IP is expressed in a range of normal and fetal tissues unlike SSX2. SSX2IP containing constructs indicated that SSX2IP could be expressed in the nucleus and cytoplasm of transfected human cells, however, SSX2IP expression has been subsequently shown to peak on the surface of myeloid leukaemia cells during mitosis. Here we discuss the current knowledge of SSX2IP function in several species and the growing evidence that SSX2IP may be a suitable target for leukaemia immunotherapy. |
